Lakesha Jones, NP
Psychiatric/Mental Health · Colton, CANPI 1649804469
Payments from drug & device makers
Across 231 payments — averaging $31.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$906
- AbbVie$896
- Alkermes, Inc.$830
- Johnson & Johnson$811
- Teva Pharmaceuticals USA, Inc.$735
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,372100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 22 | $1,039 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $906 |
| AbbVie | 27 | $896 |
| Alkermes, Inc. | 30 | $830 |
| Johnson & Johnson | 17 | $811 |
| Teva Pharmaceuticals USA, Inc. | 43 | $735 |
| Novo Nordisk | 3 | $367 |
| Vanda Pharmaceuticals Inc. | 17 | $310 |
| Lundbeck LLC | 16 | $238 |
| Otsuka America Pharmaceutical, Inc. | 9 | $186 |
| Si-bone, Inc. | 1 | $133 |
| Edwards Lifesciences | 2 | $126 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $118 |
| Scynexis, Inc. | 1 | $101 |
| Hydrofera LLC | 1 | $91 |
| Gilead | 1 | $85 |
| AstraZeneca | 1 | $70 |
| Idorsia Pharmaceuticals US Inc | 3 | $57 |
| Almatica Pharma LLC | 2 | $57 |
| Supernus Pharmaceuticals, Inc. | 1 | $48 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$909
- INGREZZA$515
- VRAYLAR$489
- LYBALVI$480
- CAPLYTA$480
- INVEGA SUSTENNA$247
- ARISTADA INITIO$227
- RYBELSUS$125
- SPRAVATO$125
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$125
- XARELTO$124
- DUPIXENT$122
- AUSTEDO$122
- Ozempic$120
How this compares
$7,373 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 40 | $61,761 |
| Invega SustennaPaliperidone Palmitate | 14 | $47,290 |
| UzedyRisperidone | 11 | $37,402 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $26,980 |
| VraylarCariprazine Hcl | 15 | $24,211 |
| Aripiprazole | 100 | $3,112 |
| Quetiapine Fumarate | 182 | $2,329 |
| Ramelteon | 36 | $2,233 |
| Bupropion XlBupropion Hcl | 31 | $2,178 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $1,799 |
| Sertraline Hcl | 124 | $1,425 |
| Buspirone Hcl | 94 | $1,113 |
| Hydroxyzine Pamoate | 47 | $1,072 |
| Olanzapine | 108 | $1,057 |
| Risperidone | 62 | $857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $906 | $61,76140 claims |
| Johnson & JohnsonInvega Sustenna | $811 | $47,29014 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $735 | $37,40211 claims |
| Alkermes, Inc.Lybalvi | $830 | $26,98019 claims |
| AbbVieVraylar | $896 | $24,21115 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $1,425124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Colton
- Khadija HamisiColton$18K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.